The OXE receptor: a new therapeutic approach for asthma?
The eicosanoid 5-oxo-6E,8Z,11Z,14Z-eicosatetraenoic acid (5-oxo-ETE) has recently been identified as the ligand for the oxoeicosanoid (OXE) receptor. In vitro and in vivo studies have suggested that 5-oxo-ETE has a role in the asthmatic inflammatory response and it has been shown to stimulate eosinophil migration to the airways. New data suggest that eosinophils have an important role in the pathogenesis of asthma, being required for mucus accumulation, airway hyperresponsiveness and remodelling of the airways. However, there are several mediators that can stimulate the recruitment of eosinophils to the airways and the development of antagonists against the OXE receptor is required to evaluate the potential of the OXE receptor as a new therapeutic approach for asthma.
Jones
Carol E
CE
Respiratory Diseases Therapeutic Area, Novartis Institutes for Biomedical Research, Horsham, RH12 5AB, UK. carol-e.jones@novartis.com
D000818:Animals; D001094:Arachidonate 5-Lipoxygenase / Q000378:metabolism*; D001095:Arachidonic Acids / Q000737:chemistry*; D001249:Asthma / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D016535:Bronchial Hyperreactivity / Q000473:pathology; D002630:Chemotactic Factors / Q000494:pharmacology*; D004804:Eosinophils / Q000378:metabolism; D006801:Humans; D007249:Inflammation; D008954:Models, Biological; D009000:Monocytes / Q000378:metabolism; D009504:Neutrophils / Q000378:metabolism
D001095:Arachidonic Acids; D002630:Chemotactic Factors; C080828:5-oxo-6,8,11,14-eicosatetraenoic acid; D001094:Arachidonate 5-Lipoxygenase